SCHEMBL14537505

SCHEMBL14537505

COc1ccc(Nc2nc(Cl)nc(Cl)n2)cc1CI

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.51
▸ GAA P10253 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ KMT2A Q03164 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ NFKB1 P19838 4/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ APP P05067 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ PTK2 Q05397 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ ABCG2 Q9UNQ0 1/20 0.42
▸ AGPAT2 O15120 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14421535 0.87 RAB9A (0.50) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL14421434 0.84 ABCG2 (0.46) MAPTGAANPC1RAB9AKMT2A
SCHEMBL14533521 0.84 RAB9A (0.58) MAPTSMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL14615386 0.84 MAPT (0.41) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL14421466 0.83 MAPT (0.61) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL13326018 0.82 MAPT (0.59) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL4832464 0.81 MAPT (0.75) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL4835357 0.78 APP (0.59) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL4829511 0.78 MAPT (0.75) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL4836537 0.75 APP (0.63) MAPTGAASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070117795-A1 Methods and compositions of novel triazine compounds DR. REDDY'S LABORATORIES LTD. (IN) 2007-05-24 — — US disclosed
US-7169784-B2 Medical devices employing triazine compounds and compositions thereof REDDY US THERAPEUTICS, INC. (US) 2007-01-30 — — US disclosed
US-7163943-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-16 — — US disclosed
US-20070004729-A1 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004729-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS MAPT 3539/4885GAA 852/4885SMN1; SMN2 4172/4885
US-20070117795-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS MAPT 3539/4885GAA 852/4885SMN1; SMN2 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback